JNJ vs SAVA

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Cassava Sciences continues to face an existential crisis due to unresolved allegations of data manipulation and ongoing regulatory investigations by the FDA and NIH concerning its lead drug candidate, simufilam. While the Alzheimer's market offers theoretical 10x growth potential, this is fundamentally undermined by a profound trust deficit in leadership and the scientific integrity of their core ...